Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495389 | 0.90 | HPGDS (0.58) | HPGDSCA1CA2RORCMAPT | |
| SCHEMBL16496112 | 0.89 | HPGDS (0.56) | HPGDSRORCMAPTMEN1KMT2A | |
| SCHEMBL16495531 | 0.89 | CA2 (0.67) | HPGDSCA1CA2MEN1KMT2A | |
| SCHEMBL16496440 | 0.89 | HPGDS (0.72) | HPGDSCA1CA2RORCALDH1A1 | |
| SCHEMBL16495684 | 0.87 | HPGDS (0.53) | HPGDSRORCMAPTALDH1A1MEN1 | |
| SCHEMBL16495662 | 0.87 | HPGDS (0.65) | HPGDSCA1CA2NAMPT | |
| SCHEMBL16495479 | 0.85 | HPGDS (0.77) | HPGDSALDH1A1 | |
| SCHEMBL16495648 | 0.84 | HPGDS (0.61) | HPGDSCA1CA2 | |
| SCHEMBL16496197 | 0.84 | HPGDS (0.61) | HPGDSMEN1KMT2ANAMPTPOLB | |
| SCHEMBL16495588 | 0.84 | HPGDS (0.61) | HPGDSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885CA1 3744/4885CA2 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.